CERE
Cerevel Therapeutics Holdings, Inc. Common StockCERE
CERE
Delisted
CERE was delisted on the 31st of July, 2024.
About: Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
Employees: 355
Financial journalist opinion
Neutral
Accesswire
1 month ago
CERE DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / WHY: New York, N.Y., June 3, 2025.
Neutral
Business Wire
1 month ago
CERE Investors Have the Opportunity to Lead the Cerevel Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
NEW YORK--(BUSINESS WIRE)---- $CERE #CERE--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE), Bain Capital Investors, LLC (“Bain”) and Pfizer, Inc. (“Pfizer”) and reminds investors of the June 3, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities l.
Neutral
Accesswire
1 month ago
FINAL REMINDER CERE DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Cerevel Therapeutics Holdings, Inc. Investors to Participate in the Class Action Lawsuit
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
Neutral
GlobeNewsWire
1 month ago
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the Company”) (NASDAQ: CERE), Bain Capital Investors, LLC (“Bain”) and Pfizer, Inc. (“Pfizer”).
Neutral
GlobeNewsWire
1 month ago
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options
Neutral
Accesswire
1 month ago
FINAL CERE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cerevel Therapeutics Holdings, Inc. Investors to Join the Class Action Lawsuit
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
Neutral
Accesswire
1 month ago
CERE FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / WHY: New York, N.Y., June 1, 2025.
Neutral
GlobeNewsWire
1 month ago
CERE DEADLINE TUESDAY: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that (1) sold or otherwise disposed of the publicly-traded common stock of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) during the period from October 11, 2023 through August 1, 2024, inclusive (the “Class Period”); (2) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc.; and/or (3) sold shares of Cerevel stock contemporaneously with Bain Capital's purchase of shares on or about October 16, 2023, of the important June 3, 2025 lead plaintiff deadline.
Neutral
Accesswire
1 month ago
CERE STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE), Bain Capital Investors, LLC ("Bain") and Pfizer, Inc. ("Pfizer"). Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive, and thus were damaged by defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act"); (b) held shares of Cerevel as of January 8, 2024 (the "Record Date") and were entitled to vote on the merger of Cerevel and AbbVie Inc. ("AbbVie") and thus were damaged by defendants' violations of Section 14(a) of the Exchange Act; and/or (c) sold shares of Cerevel stock contemporaneously with Bain's purchase of shares on or about October 16, 2023 and thus were damaged by Bain's violations of Section 20A of the Exchange Act.
Neutral
Accesswire
1 month ago
CERE IMPORTANT DEADLINE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE
NEW YORK CITY, NY / ACCESS Newswire / May 31, 2025 / WHY: New York, N.Y., May 31, 2025.
Charts implemented using Lightweight Charts™